Ali-Jackson Kamil sold $88K of RIGL
Ali-Jackson Kamil sold 2,500 shares of RIGEL PHARMACEUTICALS INC (RIGL) at $35.00 on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest information is the specific open-market sale size, price ($35), date (2026-06-22), and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may briefly reassess sentiment around insider activity, but the 10b5-1 structure makes it less likely to drive a durable repricing.
What to watch
The filing does not disclose any new operational, clinical, or financial catalyst—only the transaction details and post-sale holdings.
Background
This is an SEC Form 4 insider transaction disclosure for RIGEL PHARMACEUTICALS, reported by a director.
Ticker impact
RIGEL PHARMACEUTICALS director Ali-Jackson Kamil filed a Form 4 open-market sale of 2,500 shares at $35 on 2026-06-22.
Likely limited immediate price impact; any reaction would be sentiment-driven rather than fundamental.
The filing is a routine director sale (2,500 shares) explicitly under a pre-arranged Rule 10b5-1 plan, which reduces interpretive value versus discretionary selling.
Market effects
No sector-level read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations, so traders may ignore it.
Key entities
- issuerRIGEL PHARMACEUTICALS INC
Subject of the Form 4 insider transaction; director sold shares under a 10b5-1 plan.
- insiderAli-Jackson Kamil
Director who reported the open-market sale of 2,500 shares.
